
Jason Keith Sicklick MD FACS (He/Him)
Hepatobiliary Surgery, Surgical Oncology (Other than Breast)
Professor of Surgery, UC San Diego School of Medicine
Join to View Full Profile
3855 Health Sciences DrLa Jolla, CA 92093
Phone+1 858-822-6173
Fax+1 858-228-5153
Dr. Sicklick is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jason Sicklick is an NIH and FDA R01 funded investigator, Professor of Surgery, Executive Vice Chair of Research in the Department of Surgery, and Co-Leader of the Sarcoma Disease Team at the UC San Diego Moores Cancer Center. He is a board-certified general surgeon and surgical oncologist specializing in the treatment of complex retroperitoneal and abdominal sarcomas, including gastrointestinal stromal tumors (GIST), as well as hepatobiliary oncology. In 2016, Dr. Sicklick was named the GIST Clinician of the Year by the Life Raft GIST Support Group, the largest GIST patient advocacy group in the world. In 2018, Dr. Sicklick was selected as a James IV Association of Surgeons fellow. This highly prestigious international traveling fellowship is designed to promote communication and collaboration in the international surgical community. In 2018 he also received the RARE Champion of Hope in Medical Care & Treatment Award from the Global Genes-Allies in Rare Disease, the largest global non-profit advocacy organization for individuals and families fighting rare and genetic diseases. In 2019, he received the Excellence in Mentoring Award from the UC San Diego Health Systems International. In 2021, he received the Rare Impact Award from the National Organization for Rare Disorders (NORD®), which aims to provide support for individuals with rare diseases by advocating and funding research, education, and networking among service providers.
He received his medical degree from the UCLA School of Medicine, completed his general surgery residency at The Johns Hopkins Hospital where he was the Administrative Chief Resident, and completed a fellowship in surgical oncology at Memorial Sloan Kettering Cancer Center where he was the Chief Administrative Fellow. He joined the UC San Diego Division of Surgical Oncology at Moores Cancer Center in 2010.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2008 - 2010
Johns Hopkins UniversityResidency, Surgery, 2000 - 2008
David Geffen School of Medicine at UCLAClass of 2000
Certifications & Licensure
CA State Medical License 2010 - 2028
NY State Medical License 2008 - 2011
American Board of Surgery Surgery
Awards, Honors, & Recognition
- Top Doctors:San Diego Area Castle Connolly, 2013-2019
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
Clinical Trials
- LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis Start of enrollment: 2014 Jul 01
- Study of Molecular Profile-Related Evidence to Determine Individualized Therapy for Advanced or Poor Prognosis Cancers Start of enrollment: 2015 Feb 01
- Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) Start of enrollment: 2018 Sep 12
Roles: Contact, Principal Investigator, Sub-Investigator
Publications & Presentations
PubMed
- Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individua...Jason K Sicklick, Daisuke Nishizaki, Hirotaka Miyashita, Ryosuke Okamura, Michael E Hahn
Journal of Clinical Oncology. 2026-01-08 - CD40 transcriptomic expression patterns across malignancies: implications for clinical trials of CD40 agonists.Yuji Uehara, Daisuke Nishizaki, Yu Fujiwara, Hirotaka Miyashita, Suzanna Lee
Cancer Immunology, Immunotherapy. 2025-11-03 - 5 citationsCancer treatment paradigms in the precision medicine era.Vivek Subbiah, Giuseppe Curigliano, Jason K Sicklick, Shumei Kato, Kjetil Tasken
Nature Medicine. 2025-11-01
Journal Articles
- Advanced Basal Cell Cancer: Concise Review of Molecular Characteristics and Novel Targeted and Immune TherapeuticsJ K Sicklick, P R Cohen, Annals of Oncology
- Tumor Symbiosis: Gastrointestinal Stromal Tumor as a Host for Primary Peritoneal MesotheliomaSudeep Banerjee, Adam M Burgoyne, Joel Baumgartner, Amanda Kirane, Grace Y Lin, Jason Sicklick, Journal of gastrointestinal surgery
- Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma DatabaseJohn Phay, Lawrence A Shirley, Lauren M Postlewait, Carmen C Solorzano, Colleen M Kiernan, Ioannis Hatzaras, Natalie Seiser, Tracy S Wang, Ryan C Fields, Konstantinos ..., Annals of Surgical Oncology
Press Mentions
San Diego’s Top Doctors: The Annual List, 2025September 30th, 2025
Study Suggests Relationship Between Stromal Tumors and MesotheliomaAugust 2nd, 2022
Ripretinib Continues to Demonstrate Benefit in Advanced GISTNovember 11th, 2021
Grant Support
- Prognostic and Therapeutic Roles of Voltage Gated Potassium Channels in Managing KIT Mutant Gastrointestinal Stromal Tumors (GIST)UNIVERSITY OF CALIFORNIA, SAN DIEGO2025–2030
- National Succinate Dehydrogenase-deficient GIST Translational Research and Clinical Trial ConsortiumUNIVERSITY OF CALIFORNIA, SAN DIEGO2024–2029
- Surgical Oncologists as Scientists (SOAS) Training ProgramUNIVERSITY OF CALIFORNIA, SAN DIEGO2023–2028
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









